Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients -October 02, 2023 at 08:09 am EDT

Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects identified a candidate dose that is unlikely to require therapeutic drug monitoring




Safety...

Related Keywords

Florida ,United States ,Americans ,Stephan Jackman ,Exchange Commission ,Drug Administration ,Nasdaq ,Securities Exchange ,Alzamend Neuro Inc ,University Of South Florida Research Foundation Inc ,Alzamend Neuro ,Chief Executive Officer ,New Drug Application ,South Florida Research Foundation ,Securities Act ,Securities Exchange Act ,Markets ,